

## Summary of minutes of EUCAST Steering Committee Meeting Vienna, Austria, 13-14 April 2010

### Attending

Dr Derek F.J. Brown	DB	Scientific Secretary	United Kingdom
Dr Rafael Cantón	RC	Clinical Data Co-ordinator	Spain
Dr Christian Giske	CG	SRGA	Sweden
Dr Antti Hakanen	AH	EUCAST	Finland
Prof Gunnar Kahlmeter	GK	Chairperson	Sweden
Prof Alasdair P. MacGowan	AM	BSAC	United Kingdom
Dr Johan W. Mouton	JM	CRG	The Netherlands
Prof Arne Rodloff	AR	DIN	Germany
Dr Martin Steinbakk	MS	NWGA	Norway
Prof Paul Tulkens	PT	EUCAST	Belgium

### Apologies

Prof Claude-James Soussy	CS	CA-SFM	France
--------------------------	----	--------	--------

### Present for item 7, AFST subcommittee members

Dr Maiken Cavling Arendrup	MA	Denmark
Dr Manuel Cuenca-Estrella	MC	Spain
Dr Juan Luis Rodriguez-Tudela	JR	Spain (Chair)

1	<b>Chairman's welcome</b>
2	<b>Minutes of meeting of 8-9 February 2010</b> The minutes were accepted as a correct record.
3	<b>Matters arising from minutes of 8-9 February 2010</b> A paper for CMI explaining ECOFFs is to be prepared. MIC data on anaerobes, <i>H. pylori</i> and mycobacteria are being collected. The new version of EUCAST Expert Rules and associated publications should be available soon.
4	<b>New drugs</b> Ceftobiprole license has been refused by EMA. See EMA website for details.  A response from the company is awaited to breakpoints proposed for a new glycopeptide.
5	<b>Status of EUCAST rationale documents</b> The status and content of several documents was reviewed. Metronidazole and nitrofurantoin documents have been released. Vancomycin, teicoplanin, erythromycin, clarithromycin and colistin documents are very close to completion.
6	<b>Breakpoints/ expert rules for ESBLs</b> There were no comments on recent proposals, which were finalised, i.e. cefotaxime and ceftriaxone S $\leq$ 1, R>2 mg/L, ceftazidime, cefepime and aztreonam S $\leq$ 1, R >4 mg/L, susceptibility to be reported as found. Expert rules will be changed accordingly.
7	<b>Expert rules subcommittee</b> The revised version of the expert rules document will be finalised.
8	<b>Antifungal susceptibility testing subcommittee</b> A joint meeting with subcommittee members discussed current and future activities.
9	<b>Anaerobe subcommittee</b> A study of different susceptibility testing methods is underway.
10	<b>Organisms without EUCAST breakpoints</b> Meetings will be organised with <i>Helicobacter</i> and <i>C. difficile</i> study groups. Work is planned or underway on <i>Campylobacter</i> , <i>Legionella</i> , <i>Listeria</i> and <i>Pasteurella multocida</i> .
11	<b>Breakpoints for mupirocin</b> Following discussion of comments on proposals for breakpoints of S $\leq$ 2, R >256 mg/L, it was agreed to consult on revised proposals for S $\leq$ 1, R >256 mg/L.
12	<b>Breakpoints for colistin</b> Breakpoints for <i>P. aeruginosa</i> of S $\leq$ 4, R >4 mg/L were widely supported in the recent consultation and were agreed.
13	<b>ECCMID</b> The ECCMID 2010 workshop, symposium, meet the experts session, debate on ESBLs

and General Committee Meeting went well and were very well attended. Topics proposed for the ECCMID 2011 meeting will be sent to the organising committee.

The Postgraduate course on susceptibility testing and resistance surveillance will be in Madrid, Monday 27 to Thursday 30 September 2010.

- 14 CLSI** The proposed carbapenem addendum to the 2010 breakpoints is awaited.
- 15 ECDC** The next Steering Committee meeting in Stockholm will be party held at ECDC.
- 16 EMA** Draft EMA guidance for industry on the data needed for registration of new antibacterial drugs has been distributed for comment. EMA will be invited to attend the Stockholm meeting to discuss the draft and other issues.
- 17 Implementation of EUCAST breakpoints** A document on the readiness of commercial manufacturers to implement EUCAST breakpoints will be posted on the EUCAST website. Updated breakpoint and QC tables are close to completion. A question and answer file for the disk diffusion method is being prepared.
- 18 New tetracycline agent** A preliminary presentation was given by the company.
- 19 Agents without breakpoints** Agents to be given breakpoints were reviewed. Data will be collected for the 20 agents given priority.
- 20 Oxacillin breakpoints for coagulase-negative staphylococci** More MIC distributions are needed specifically for *S. saprophyticus*.
- 21 New macrocyclic agent** Breakpoints were discussed.
- 22 Breakpoint format for the intermediate category** S is  $\leq x$  mg/L, R is  $> y$  mg/L, I is  $> x$  to  $y$  mg/L; eg for imipenem with Enterobacteriaceae S is  $\leq 2$  mg/L, R is  $> 8$  mg/L, I is  $> 2$  to 8 mg/L.
- 23 Meaning of “-” and “IE” in breakpoint tables** “-” means that the agent should not be used. In place of – it could be reported resistant. “IE” means that the organism could be a target but that there is no evidence of efficacy. In place of IE an MIC could be reported, with or without comment.
- 24 Carbapenem breakpoints for beta-haemolytic streptococci** For consistency, it was agreed to remove carbapenems breakpoints and add the same note as used for other beta-lactams.
- 25 Any other business**  
Steering Committee structure will need to be reviewed in the future as multiple countries set up national antibiotic committees and their representation might be increased.  
  
Use of EUCAST website is increasing rapidly (recently 17,000 hits per month).  
  
Dr Bob Rennie gave a presentation on a method of biofilm susceptibility testing.  
  
AH and PT have completed their terms of office on the Steering Committee and were thanked for their very significant contributions:
- 26 Next meetings**  
5-6 July 2010, Stockholm, Sweden.  
26-27 September 2010, Madrid, Spain.  
22-23 November 2010, Basel, Switzerland.  
14-15 February 2011, Vienna, Austria.  
10-11 May 2011, Milan, Italy (after ECCMID).  
11-12 July 2011, Stockholm, Sweden.  
5-6 September 2011, Munich, Germany

Ratified summary of minutes of meeting 13-14 April 2010. Prepared by DB, GK and RC